GlassScriptPhysician profile
Nicholas S Papanos
NPI 1134110448
$3,348.35
in general payments reported to CMS, 2019-2025
30 companies · $758 in 2025
The $758 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $165 · 2021: $703 · 2022: $408 · 2023: $258 · 2024: $627 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,605 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.97 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $467.12 | 2022-2025 | Rexulti |
| Lundbeck LLC | $419.27 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $333.35 | 2019-2022 | |
| Astellas Pharma US INC | $279.91 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $225.64 | 2019-2022 | |
| Alpha Cognition USA, INC. | $205.29 | 2025 | Zunveyl |
| Sumitomo Pharma America, INC. | $188.49 | 2023-2024 | Gemtesa |
| Lilly USA, LLC | $181.34 | 2019-2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $181.17 | 2019-2022 | |
| Biogen, INC. | $156.27 | 2021-2025 | Zurzuvae |
| E.R. Squibb & Sons, L.L.C. | $78.39 | 2021-2025 | Eliquis, Cobenfy |
| Astrazeneca Pharmaceuticals LP | $76.17 | 2024 | Farxiga |
| Amarin Pharma, INC. | $68.05 | 2020-2022 | |
| Pfizer INC. | $64.29 | 2023 | |
| Abbvie INC. | $52.70 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $50.84 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $46.50 | 2023-2025 | Repatha, Otezla, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $37.97 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.25 | 2021-2022 | |
| Novo Nordisk INC | $31.33 | 2024 | Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $25.04 | 2021 | |
| Eisai INC. | $24.24 | 2021 | |
| Greenwich Biosciences, INC. | $23.37 | 2021 | |
| Alkermes, INC. | $22.65 | 2024 | Aristada, Lybalvi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.97 | 2024 | Rexulti |
| Urovant Sciences INC | $14.46 | 2022 | |
| Scilex Pharmaceuticals INC. | $12.31 | 2019 | |
| Allergan, INC. | $12.27 | 2019 | |
| Sunovion Pharmaceuticals INC. | $11.70 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$20,640.20 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Papanos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.